NACFC Abstracts

Vertex at the 26th Annual North American Cystic Fibrosis Conference

Abstracts available online at the NACFC website

Orange County Convention Center | Orlando, Florida
October 11-13, 2012

Media Contacts: 617-444-6992
Dawn Kalmar
Megan Goulart
Zachry Barber

Investor Relations Contacts:
Michael Partridge (617) 444-6108
Kelly Lewis (617) 444-7530

Oral Presentations*

October 11, 2012
10:55 a.m. EDT
Hyperpolarized Gas MRI of Ivacaftor Therapy in Persons with Cystic Fibrosis and the G551D-CFT Mutation.
Talissa Altes, M.D.
October 11, 2012
11:40 a.m. EDT
The Investigational CFTR Corrector, VX-809 (Lumacaftor) Co-Administered with the Oral Potentiator Ivacaftor Improved CFTR and Lung Function in F508DEL Homozygous Patients: Phase II Study Results.
Michael P. Boyle, M.D.

*All oral presentations have an accompanying poster presentation

Poster Presentations

#30: Identification and Characterization of CFTR Corrector VRT-534 (C-18).
Peter Grootenhuis, Ph.D.

#31: Ivacaftor Potentiates Multiple Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Forms.
Frederick Van Goor, Ph.D.

#196: Hyperpolarized Gas MRI of Ivacaftor Therapy in Persons with Cystic Fibrosis and the G551D-CFTR Mutation.
Talissa Altes, M.D.

#211: Long-Term Safety and Efficacy of Ivacaftor in Persons with Cystic Fibrosis who have the G551D-CFTR Mutation.
Ed McKone, M.Sc., M.D., FRCPI, B.A., M.B., B.Ch., BAO., MRCPI

#212: Patient-Reported Outcomes in Phase 3 Trials of Ivacaftor in Subjects with CF Who Have the G551D-CFTR Mutation.
Alexandra L. Quittner, Ph.D.

#214: Nutritional Status Measures Among Persons with CF Carrying the G551D-CFTR Mutation who Received Ivacaftor or Placebo in Phase 3 Clinical Trials.
Drucy Borowitz, M.D.

#235: Exposure-Response Relationship for FEV1 and Sweat Chloride in Patients with Cystic Fibrosis Treated with Ivacaftor, a CFTR Potentiator.
Jiuhong Zha, Ph.D.

#236: Clinical Pharmacology Profile of Ivacaftor, a CFTR Potentiator.
Jiuhong Zha, Ph.D.

#249: Lung Clearance Index to Evaluate the Effect of Ivacaftor on Lung Function in Subjects with CF who have the G551D-CFTR Mutation and Mild Lung Disease.
Jane Davies, M.D., MBChB, MRCP

#260: The Investigational CFTR Corrector, VX-809 (Lumacaftor) Co-Administered with the Oral Potentiator Ivacaftor Improved CFTR and Lung Function in F508DEL Homozygous Patients: Phase II Study Results.
Michael P. Boyle, M.D.